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Abstract 
Background: To investigate the effects of dyslipidemia and statin therapy on progression of diabetic retinopathy and 
diabetic macular edema in patients with type 2 diabetes.
Methods: The medical records of 110 patients with type 2 diabetes (70 statin users and 40 non‑users) were retro‑
spectively reviewed. The two outcome measures were progression of diabetic retinopathy by two or more steps on 
the early treatment diabetic retinopathy study scale and diabetic macular edema based on optical coherence tomog‑
raphy. Serum lipid profiles were analyzed from 6 months prior to diagnosis of diabetic macular edema.
Results: Diabetic retinopathy progressed in 23% of statin users and 18% of non‑users (p = 0.506), but diabetic macu‑
lar edema was present in 23% of statin users and 48% of non‑users (p = 0.008). Statins reduced low‑density lipopro‑
tein cholesterol levels in patients with and without diabetic macular edema (p = 0.043 and p = 0.031, respectively). 
Among statin users, patients with diabetic macular edema had higher levels of triglycerides (p = 0.004) and lower 
levels of high‑density lipoprotein cholesterol (p = 0.033) than those without diabetic macular edema. Logistic regres‑
sion analysis showed that statin use significantly lowered the risk of diabetic macular edema [odds ratio (OR): 0.33, 
95% confidence interval (CI) 0.12–0.91, p = 0.032]. Hypertriglyceridemia at 6 months prior to development of macular 
edema was significantly associated with central retinal thickness (OR: 1.52; 95% CI 1.14–2.02, p = 0.005).
Conclusions: Lipid lowering therapy with statins protected against the development of diabetic macular edema and 
progression of diabetic retinopathy in patients with type 2 diabetes. Hypertriglyceridemia could be used as a surro‑
gate marker for diabetic macular edema.
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Background
Lipid-lowering therapy with hydroxymethylglutaryl-
CoA reductase inhibitors (statins) prevents major 
cardiovascular events and reduces mortality in patients 
with diabetes mellitus [1, 2]. However, recent studies 
found that statin use is associated with a small but sig-
nificant increased risk for development of diabetes [3–
5]. In contrast to these findings, the effect of statins on 
development of diabetic microvascular complications is 
unknown. A nationwide study in Denmark reported that 
statin users had a lower cumulative incidence of diabetic 
retinopathy (DR) and neuropathy before the diagnosis of 
diabetes [6]. On the other hand, Mansi et al. [5] reported 
that statin use was associated with an increased risk of 
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diabetic complications in their study of propensity score-
matched healthy statin users and non-users. Although 
these individual studies showed different results, the 
American College of Cardiology (ACC) and the Ameri-
can Heart Association (AHA) recently recommended 
statins for all people with diabetes between the ages of 40 
and 75 years-old who have low-density lipoprotein (LDL) 
cholesterol of 70 mg/dL and above. If these guidelines are 
followed, it would make statins the second-most widely 
prescribed medication in the world, after hypoglycemic 
agents for treatment of diabetes [7]. However, the effect 
of statin use on the development of diabetic macular 
edema and progression of DR in patients with pre-exist-
ing type 2 diabetes is unknown.
DR is a microvascular complication of diabetes result-
ing from hyperglycemia and glucose-related hyperosmo-
larity, and diabetic macular edema is a leading cause of 
severe vision loss in patients with DR [8–10]. While the 
key factors for progression of DR and diabetic macular 
edema is known to be associated with the duration of 
diabetes and hypertension, dyslipidemia is considered a 
risk factor for DR and diabetic macular edema too [11–
13]. Previous cohort studies suggested that increased lev-
els of total cholesterol, triglycerides, and LDL cholesterol 
had positive associations with diabetic macular edema 
in patients with type 1 diabetes [14, 15]. The fenofibrate 
intervention and event lowering in diabetes (FIELD) 
study found that fenofibrate reduced the progression of 
DR in patients with type 2 diabetes [16, 17]. The action 
to control cardiovascular risk in diabetes (ACCORD) 
eye study examined the effects of fenofibrate on DR and 
showed that fenofibrate  +  simvastatin therapy slowed 
the progression of DR in patients with type 2 diabetes 
at 4  years [17, 18], although a follow-up study reported 
that fenofibrate provided no benefit at 8 years [17, 19]. A 
recent meta-analysis of the relationship of dyslipidemia 
with diabetic macular edema reported that most studies 
focused on the prevention of progression of DR, not on 
diabetic macular edema, because diabetic macular edema 
is not currently an indication for lipid lowering therapy 
[20].
The present study investigated the effect of statin 
administration and dyslipidemia on the development of 
diabetic macular edema in patients with type 2 diabe-
tes. We also investigated the use of serum lipid profile as 
a surrogate maker for development of diabetic macular 
edema.
Methods
The medical records of 1127 patients diagnosed with 
type 2 diabetes and followed-up by the Ophthalmol-
ogy Department of Ajou University Hospital (Suwon, 
Korea) from January 2010 to October 2015 were 
retrospectively reviewed. This study was approved 
by the Institutional Review Board of Ajou University 
Hospital and complied with the Declaration of Hel-
sinki. The following demographic and clinical factors 
were obtained from medical records: age, sex, dura-
tion of diabetes, follow-up period, presence of hyper-
tension, treatment with hypoglycemic agents and/or 
statins, ocular treatment with intravitreal anti-vascular 
endothelial growth factor (VEGF) injections, HbA1c 
level, and serum lipid profile.
The severity of DR was graded using the early treat-
ment DR study (ETDRS) scale, with seven-field stereo 
photographs and fluorescein angiography performed 
simultaneously [21]. Diabetic macular edema was defined 
as retinal thickening in the macular area of either eye, 
according to the ETDRS scale, and identified by optical 
coherence tomography (OCT) [22]. Patients with diabetic 
macular edema were defined as those who developed 
macular edema during the follow-up period. Central reti-
nal thickness in cases with diabetic macular edema was 
measured as the distance from the hyperreflective line 
of the internal limiting membrane to the hyperreflective 
line of the retinal pigment epithelium/Bruch’s membrane 
complex using OCT [23]. Patients were excluded if they 
had follow-ups for less than 1 year, fewer than 2 fundus 
photographs, other retinal diseases, no DR, vitrectomy, 
use of lipid-lowering agents other than statins (such as 
fenofibrate, niacin, and/or fish oil), and no records on use 
of systemic medications.
The primary outcome measures were progression of 
DR by two or more steps on the ETDRS scale [16] and 
diabetic macular edema involving the fovea with central 
retinal thickness of 300 μm or more based on OCT find-
ings. Serum lipid profiles and other laboratory data were 
analyzed from 6 months before to 12 months after diag-
nosis of diabetic macular edema to assess the effect of 
serum lipid profile. The condition of patients without dia-
betic macular edema was confirmed during entire study 
period, and laboratory data were analyzed at the time of 
the final fundus angiography.
Pearson correlation analysis and a generalized estimat-
ing equation model were used to analyze the correlation 
of variables with central retinal thickness in patients with 
diabetic macular edema at 1, 3 and 6  months prior to 
diagnosis. Logistic regression analysis was performed to 
evaluate the association between statin use and diabetic 
macular edema after controlling for age, duration of dia-
betes, HbA1c, and lipid profiles. Categorical variables 
were compared using the Chi square test, and continuous 
variables using the independent t test. Statistical analysis 
was performed using SPSS software (version 23.0, SPSS, 
Chicago, IL). Statistical significance was defined as a p 
value less than 0.05.
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Results
We initially examined the records 1127 patients with type 
2 diabetes, and ultimately enrolled 110 patients (58 males 
and 52 females) who had DR. Table 1 summarizes demo-
graphic and clinical characteristics of patients who used 
statins (n = 70) and did not use statins (n = 40). Statin 
users were older (p =  0.016) and had a longer duration 
of diabetes (p =  0.019). DR progressed in 23% of statin 
users and 18% of non-users (p = 0.506). Notably, 16 of 70 
statin users (23%) and 19 of 40 non-users (48%) showed 
diabetic macular edema based on OCT findings during 
the follow-up period (p = 0.008). Analysis of laboratory 
profiles indicated the statin users and non-users had no 
differences in the levels of HbA1c, triglycerides, and total 
and high-density lipoprotein (HDL) cholesterol. How-
ever, statin users had significantly lower levels of LDL 
cholesterol (p = 0.007).
Subgroup analysis of patients with and without dia-
betic macular edema indicated that LDL cholesterol was 
significantly lower in statin users with and without dia-
betic macular edema (p = 0.043 and p = 0.031, respec-
tively, Table 2). These results suggest that lipid lowering 
therapy with statins protected against the development of 
diabetic macular edema without increasing the risk of DR 
progression.
Despite this beneficial effect of statins, analysis of statin 
users indicated that those with diabetic macular edema 
had a significantly higher level of triglycerides (p = 0.004) 
and a lower level of HDL cholesterol (p  =  0.033) 
(Table 3). This result suggests that hypertriglyceridemia, 
rather than dyslipidemia, may lead to the development 
of diabetic macular edema in statin users. There were 
similar trends in non-users of statins, but the differences 
were not statistically significant (data not shown). Logis-
tic regression analysis was performed to evaluate factors 
associated with diabetic macular edema (Table 4). Statin 
use was associated with a significantly lower risk of dia-
betic macular edema (odd ratio (OR): 0.40; 95% confi-
dence interval (CI) 0.17–0.90; p  =  0.028). Triglycerides 
level was associated with diabetic macular edema, while 
HDL cholesterol level lowered the risk. When adjusted 
with age, duration of diabetes, HbA1c, triglycerides and 
HDL cholesterol in multivariate analysis, statin use had 
a significant protective effect on diabetic macular edema 
(OR: 0.33; 95% CI 0.12–0.91; p = 0.032).
We also examined serum lipid profiles and HbA1c 
levels from 6  months prior to 12  months after diagno-
sis of diabetic macular edema in all patients to investi-
gate the effect of these variables on disease progression 
(Table  5). The results indicate that the levels of HbA1c, 
triglycerides, total cholesterol, and HDL cholesterol 
correlated with central retinal thickness. Specifically, 
the levels of triglycerides at 6  months prior to diabetic 
macular edema, HbA1c at the onset and 3 months prior 
to diabetic macular edema, and total cholesterol at the 
onset and 1  month prior to diabetic macular correlated 
Table 1 Baseline characteristics of patients with diabetic retinopathy (DR) who used or did not use statins
DR diabetic retinopathy, DRSS diabetic retinopathy severity scale, HDL high-density lipoprotein, IVT intravitreal injection of anti-VEGF agents, LDL low-density 
lipoprotein, NPDR non-proliferative diabetic retinopathy, PDR proliferative diabetic retinopathy
a p value <0.05 (independent t-test or Chi square test)
Variable Statin group (n = 70) No statin group (n = 40) p value
Age 58.1 ± 11.6 52.3 ± 12.2 0.016a
Sex (male:female) 41:29 17:23 0.104
Duration of diabetes mellitus (years) 12.4 ± 8.0 8.6 ± 8.2 0.019a
Follow‑up period (months) 26.8 ± 16.9 22.9 ± 15.4 0.251
Presence of hypertension 56/70 (80%) 26/40 (65%) 0.082
Initial DR severity scale 0.445
 Mild NPDR (20–35) 17 5
 Mod‑severe NPDR (43–53) 50 30
 PDR (more than 61) 3 5
DR progression (≥2 steps of DRSS) 16/70 (23%) 7/40 (18%) 0.506
Presence of diabetic macular edema 16/70 (23%) 19/40 (48%) 0.008a
No. of IVT 1.2 ± 2.4 1.8 ± 3.0 0.317
HbA1c (%) 8.1 ± 1.7 8.0 ± 1.5 0.758
Total cholesterol (mmol/L) 4.4 ± 2.6 4.4 ± 1.5 0.904
Triglycerides (mmol/L) 1.9 ± 1.4 2.1 ± 1.5 0.569
HDL cholesterol (mmol/L) 1.1 ± 0.3 1.1 ± 0.3 0.990
LDL cholesterol (mmol/L) 2.1 ± 0.8 3.0 ± 1.3 0.007a
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positively with central retinal thickness; the HDL choles-
terol level at 3 months prior to diabetic macular edema 
had a negative correlation with central retinal thick-
ness. Furthermore, analysis using a generalized estimat-
ing equation indicated that only hypertriglyceridemia at 
6  months prior to development of macular edema was 
associated with central retinal thickness (OR 1.52; 95% 
CI 1.14–2.02, p  =  0.005). Taken together, these results 
indicate that hypertriglyceridemia is associated with 
the incidence and severity of diabetic macular edema in 
patients with type 2 diabetes who are taking statins.
Discussion
Dyslipidemia is common in patients with type 2 diabetes 
and is a well-known risk factor for atherosclerosis and 
cardiovascular diseases [24, 25]. Treatments that lower 
cholesterol, especially LDL cholesterol, reduce the risk 
of cardiovascular morbidity in many patient populations, 
although there are controversies on the overall benefits 
of intensive statin therapy [25, 26]. However, statin use 
seems to modestly increase the risk of new-onset type 
2 diabetes in individuals with a pre-existing elevated 
risk for diabetes, probably because they increase insulin 
resistance and decrease insulin secretion [3, 4]. However, 
the benefits of reduced risk of cardiovascular disease 
probably outweigh the potentially increased risk of dia-
betes [1]. A recent large retrospective cohort study with 
a follow-up period of 6.5  years reported that statin use 
significantly increased the risk of new-onset diabetes and 
diabetic complications in healthy adults [5]. Thus, statin 
Table 2 Serum lipid profiles of  patients with  diabetic 
retinopathy who had or did not have diabetic macular 
edema (DME) and who used or did not use statins
DME diabetic macular edema, HDL high-density lipoprotein, LDL low-density 
lipoprotein
a p value <0.05 (independent t-test)
Variable Statin No statin p value
DME group (no. of patients) 16 19
 HbA1c (%) 7.7 ± 1.2 7.9 ± 1.6 0.642
 Total cholesterol (mmol/l) 4.7 ± 1.5 5.0 ± 1.2 0.501
 Triglycerides (mmol/l) 3.0 ± 2.7 2.3 ± 1.4 0.388
 HDL cholesterol (mmol/l) 0.9 ± 0.3 1.0 ± 0.4 0.410
 LDL cholesterol (mmol/l) 2.2 ± 0.8 3.2 ± 1.1 0.043a
No DME group (no. of patients) 54 21
 HbA1c (%) 8.2 ± 1.7 8.2 ± 1.7 0.932
 Total cholesterol (mmol/L) 4.3 ± 2.8 4.2 ± 1.6 0.866
 Triglycerides (mmol/L) 1.7 ± 0.9 1.9 ± 0.8 0.246
 HDL cholesterol (mmol/L) 1.1 ± 0.4 1.2 ± 0.3 0.916
 LDL cholesterol (mmol/L) 2.1 ± 0.8 2.8 ± 1.3 0.031a
Table 3 Serum lipid profiles of  patients with  diabetic 
retinopathy who used or did not use statins and who had 
or did not have diabetic macular edema (DME)
DME diabetic macular edema, HDL high-density lipoprotein, LDL low-density 
lipoprotein
a p value <0.05 (independent t-test)
Variable DME No DME p value
Statin group (no. of patients) 16 54
 HbA1c (%) 7.7 ± 1.2 8.2 ± 1.7 0.282
 Total cholesterol (mmol/L) 4.7 ± 1.5 4.3 ± 2.8 0.603
 Triglycerides (mmol/L) 3.0 ± 2.7 1.7 ± 0.9 0.004a
 HDL cholesterol (mmol/L) 0.9 ± 0.3 1.1 ± 0.4 0.033a
 LDL cholesterol (mmol/L) 2.2 ± 0.8 2.1 ± 0.8 0.761
No‑statin group (no. of patients) 19 21
 HbA1c (%) 7.9 ± 1.6 8.2 ± 1.7 0.649
 Total cholesterol (mmol/L) 5.0 ± 1.2 4.2 ± 1.6 0.092
 Triglycerides (mmol/L) 2.3 ± 1.4 1.9 ± 0.8 0.349
 HDL cholesterol (mmol/L) 1.0 ± 0.4 1.2 ± 0.3 0.219
 LDL cholesterol (mmol/L) 3.2 ± 1.1 2.8 ± 1.3 0.443
Table 4 Logistic regression analysis between  patients 
with  and without  diabetic macular edema for  variables 
associated with diabetic macular edema
HDL high-density lipoprotein, LDL low-density lipoprotein
a p value <0.05 (logistic regression analysis)
Variable OR (95% CI) p value
Age 1.00 (0.97–1.04) 0.892
Duration of diabetes 1.00 (0.95–1.05) 0.843
Statin use 0.40 (0.17–0.90) 0.028a
HbA1c 0.98 (0.95–1.00) 0.091
Total cholesterol 1.11 (0.92–1.35) 0.289
Triglycerides 1.51 (1.06–2.14) 0.023a
HDL cholesterol 0.18 (0.04–0.80) 0.024a
LDL cholesterol 1.48 (0.89–2.44) 0.132
Table 5 Correlation of serum variables with central retinal 
thickness in patients with diabetic macular edema
HDL high-density lipoprotein, LDL low-density lipoprotein. The time of diagnosis 
with diabetic macular edema is ‘0 M’, 1, 3, and 6 months prior to diabetic macular 
edema are presented as ‘−1 M’, ‘−3 M’, and ‘−6 M’
a p value <0.05 (Pearson correlation analysis)
Variable Months R p value
HbA1c −3 M, 0 M 0.709 0.022a
Total cholesterol −1 M, 0 M 0.516 0.028a
Triglycerides −6 M 0.559 0.010a
HDL cholesterol −3 M −0.715 0.009a
LDL cholesterol 0.150 0.700
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use may be a serious concern for individuals with predis-
positions for diabetes or pre-existing diabetes, but few 
studies have examined the effect of statins on diabetic 
microvascular complications, especially DR and diabetic 
macular edema.
The present study of patients with type 2 diabetes and 
DR shows that statin users have lower levels of LDL cho-
lesterol than non-users. Notably, our results also show 
that statin therapy reduces the prevalence of diabetic 
macular edema in patients with type 2 diabetes and pre-
existing DR, but does not contribute to the progression of 
DR. Considering that our statin users had a significantly 
longer duration of diabetes than non-users (Table 1), and 
that duration of diabetes is the strongest predictor for 
development and progression of DR [27], these results 
suggest that statins protect against the development of 
diabetic macular edema and progression of DR. Statins 
may protect against microvascular damage in patients 
with diabetes for several reasons. First, statins may ben-
efit dyslipidemic patients with diabetes because they may 
reduce lipid leakage and improve lipid clearance in the 
eyes [28, 29]. Second, statins increase HbA1c in about 
0.3% in patients with diabetes, so that may only cause rel-
atively small exacerbations of diabetes [2]. Lastly, statins 
have anti-inflammatory effects, and this might slow the 
progression of microvascular complications in patients 
with diabetes [30, 31].
Previous studies showed that dyslipidemia is associ-
ated with diabetic macular edema [14, 32]. In addition, 
a global multicenter study reported that a high level of 
triglycerides and a low level of HDL cholesterol were 
associated with increased risk of diabetic microvascular 
diseases [33]. In our population, it is important to note 
that statin users with diabetic macular edema had a sig-
nificantly higher level of triglycerides (p =  0.004) and a 
lower level of HDL cholesterol (p  =  0.033) than those 
without diabetic macular edema, even though LDL cho-
lesterol levels were well-controlled in both groups. A 
recent meta-analysis of cohort and case–control stud-
ies in patients with type 1 and 2 diabetes showed that 
serum triglyceride level was an independent risk factor 
for diabetic macular edema [20]. Moreover, a study of 
patients with type 1 diabetes reported no evidence of a 
relationship between oxidized LDL level and the inci-
dence of diabetic macular edema or worsening of DR 
[34]. These findings motivated us to analyze the possible 
use of serum triglyceride level as a surrogate marker for 
macular edema in patients with type 2 diabetes. Indeed, 
serum triglycerides level at 6  months prior to the diag-
nosis of diabetic macular edema had a positive correla-
tion with development of diabetic macular edema and 
with increased central retinal thickness in patients with 
diabetic macular edema. These results suggest that serum 
triglyceride level could be used as a surrogate marker for 
the development and severity of macular edema.
Our findings show that triglycerides and LDL choles-
terol play important roles in the onset and severity of dia-
betic macular edema. Lipid lowering therapy with statins 
targets LDL cholesterol [7, 24, 25], but our findings indi-
cate that the triglyceride level must also be controlled 
to prevent diabetic macular edema in patients with DR. 
Current treatment guidelines for dyslipidemia focus on 
LDL cholesterol and use of statin therapy [24, 25]. New 
guidelines released by the ACC/AHA in November 2013 
recommend statin therapy for all patients with diabetes 
who are 40–75 years-old, have LDL cholesterol levels of 
70 mg/dL or more, and have a 10-year risk of cardiovas-
cular disease risk that is 7.5% or more, based on pooled 
cohort equations [7, 25]. These guidelines also suggest 
use of other therapies for patients with type 2 diabetes, 
such as fibrates, niacin, and/or fish oil, when the serum 
triglyceride level is moderately high despite statin use. 
Statin therapy can reduce triglycerides level by 10–20%, 
depending on the specific statins [35–39]. More specifi-
cally, rosuvastatin, atorvastatin, and especially pitavasta-
tin are more effective in reducing triglyceride levels than 
the older statins [35–42]. The greatest benefit was seen 
in patients with high baseline triglyceride levels [35–42]. 
Furthermore, the combined use of statin and a fibrate 
(e.g. fenofibrate and bezafibrate) more effectively lowers 
serum triglycerides than statin therapy alone [43–45]. 
The ACCORD trial reported that fenofibrate provided 
no overall benefit for patients with type 2 diabetes when 
added to a statin, but it did improve outcomes in a sub-
set of patients with elevated triglycerides (>204  mg/dL 
[2.30 mmol/L]) and low HDL cholesterol levels (<34 mg/
dL [0.88  mmol/L]) [17, 46]. Based on these consid-
erations, we suggest use of a statin with a supplemental 
therapy for patients with hypertriglyceridemia and DR to 
protect against diabetic macular edema.
Targeting triglycerides as a therapeutic indication for 
patients with type 2 diabetes would also help to reduce 
macrovascular complications such as cardiovascular 
events. Many epidemiological studies showed that DR is 
associated with macrovascular diseases in patients with 
type 2 diabetes [47]. Patients with type 2 diabetes and 
DR have an increased presence and number of plaques 
in the carotid territory [48]. The presence of dyslipidemia 
(elevated triglycerides and decreased HDL cholesterol) 
is associated with silent myocardial ischemia or angio-
graphic coronary artery disease in asymptomatic patients 
with type 2 diabetes [49].
This study has several limitations. The small number of 
patients with diabetic macular edema is the major limita-
tion. Thus, it might be difficult to generalize our results 
to other populations of patients with diabetic macular 
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edema. However, our results showed significant relation-
ships between serum triglycerides and diabetic macular 
edema, in agreement with the findings of the FIELD study 
and a recent meta-analysis of risk factors for diabetic 
macular edema [16, 20]. The present study also had a ret-
rospective design, and the patients used different doses 
and different kinds of statins. These limitations could be 
overcome by performing a prospective randomized con-
trolled trial. In addition, large and long-term randomized 
controlled prospective studies are needed to obtain a 
more complete risk/benefit assessment of the effect of 
statin therapy on DR and diabetic macular edema. Sev-
eral previous trials have compared standard-dose versus 
high-dose statin therapy for prevention of cardiovascular 
diseases [50, 51]. Similar studies are needed for DR and 
diabetic macular edema.
Conclusions
In conclusion, use of statins by patients with type 2 dia-
betes and pre-existing DR did not increase the risk of 
DR progression, but was protective against development 
of diabetic macular edema. Hypertriglyceridemia is a 
potential surrogate marker for diabetic macular edema in 
patients with type 2 diabetes. Moreover, clinicians should 
closely monitor hypertriglyceridemia in patients with 
type 2 diabetes and taking statins. Use of a statin with a 
supplemental therapy (fenofibrate, niacin, and/or fish oil) 
should be considered for patients with DR to prevent the 
onset and reduce the severity of diabetic macular edema.
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